白蛋白结合 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-07 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
=== Extracellular matrix adhesion and signaling === Integrin alpha-1 (ITGA1), when linked with Integrin beta-1 (ITGB1), forms the α1β1 Integrin receptor. The α1β1 is a transmembrane extracellular matrix (ECM) receptor that mediates cell adhesion and intracellular signaling. By binding collagen and laminin, ITGA1 allows cells to sense and respond to changes in the ECM. These interactions are how ITGA1 regulates cell-matrix adhesion, focal adhesion formation, ECM organization, and downstream pathways controlling cell survival, proliferation, migration, and differentiation. The molecular functions of ITGA1 include collagen binding, collagen-mediated cell-matrix adhesion, protein interactions involved in signaling pathways, and localizations to the cell surface, plasma membrane, focal adhesions, and integrin complexes. These attributes aid in its function as a key mediator of ECM-dependent cellular communication.
Von Willebrand disease (VWD) is a type of blood-clotting disorder. It is the most common hereditary coagulopathy in humans, affecting 1% of the population. An acquired form of VWD can sometimes result from other medical conditions. Most people with VWD have no symptoms. Those that do usually have bleeding of varying intensity, including repeated bruising and nosebleeds. VWD arises from a deficiency in the quality or quantity of von Willebrand factor (VWF), a protein required for platelet adhesion through the binding to other proteins, particularly factor VIII. The disease is known to affect several breeds of dogs as well as humans. Four types of hereditary VWD have been described, including platelet-type VWD, with VWD type 1 being the most common. Types 1 and 2 are inherited through an autosomal dominant pattern, meaning at least one parent must also have the disease. Diagnosis is typically confirmed through blood tests. Managing VWD includes the use of desmopressin after minor trauma or before surgery, which allows the body to release more VWF. The disease is named after the Finnish physician Erik Adolf von Willebrand, who first described the condition in 1926.
=== Therapeutic targeting in autoimmune disease === Therapies seek to disrupt the IgG-FcRn interaction to increase the clearance of disease-causing IgG autoantibodies from the body. One such therapy is the infusion of intravenous immunoglobulin (IVIg) to saturate FcRn's IgG recycling capacity and proportionately reduce the levels of disease-causing IgG autoantibody binding to FcRn, thereby increasing disease-causing IgG autoantibody removal. More recent approaches involve the strategy of blocking the binding of IgG to FcRn by delivering antibodies that bind with high affinity to this receptor through their Fc region or variable regions. These engineered Fc fragments or antibodies are being used in clinical trials as treatments for antibody-mediated autoimmune diseases such as primary immune thrombocytopenia and skin blistering diseases (pemphigus), and the Fc-based inhibitor, efgartigimod, based on the 'Abdeg' technology was recently approved (as 'Vyvgart') for the treatment of generalized myasthenia gravis in December 2021.
==== Jasmine ==== Marika Reimon (礼紋 茉莉花, Reimon Marika), also known as "Jasmine" (ジャスミン, Jasumin), is a calm and collected psychic, or "ESPer", who serves as Deka Yellow (デカイエロー, Deka Ierō). In the past, she suffered from depression over her then-inability to control her abilities and contemplated suicide by allowing an Alienizer to kill her. However, she was rescued and recruited by Doggie Kruger. In the present, she is good friends with her teammate Umeko, with whom she forms a tag-team called the Twin Cam Angels (ツインカム・エンジェル, Tsuin Kamu Enjeru). As of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Jasmine is married and has a son named Taiga (大我). Jasmine's ESPer abilities allow her to pick up on sensory impressions of others by handling an object connected to them or visiting a location her target has been to, though overuse of her powers exhausts her. To control her powers, she wears gloves. Furthermore, as a result of breast-feeding her son during the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Jasmine temporarily gained the ability to teleport herself to any part of the universe, which she loses as of the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster. In the crossover film Mahō Sentai Magiranger vs. Dekaranger, she displays the ability to break the fourth wall.
Sources: en.wikipedia.org
== HIV/AIDS treatment and prevention == Hamer's lab developed several biotechnological strategies to treat and reduce the transmission of HIV/AIDS. As a means to reduce the latent pools of virus responsible for viral persistence, they discovered novel chemical agent to induce integrated virus, and molecularly-engineered immunotoxins to destroy the infected cells. They also collaborated with Osel, Inc. on a novel "live microbial microbicide" approach to HIV/AIDS prevention. By genetically engineering normal vaginal bacteria to produce a potent anti-HIV peptide, significant protection against viral infection was provided in a durable and obtainable fashion for up to one month. The methodology was shown to be applicable to both rectal and vaginal use and is in the initial stages of preclinical testing.
The names of those members of the Regular SAS who have died on duty were inscribed on the regimental clock tower at Stirling Lines. Originally funded by contributions of a day's pay by members of the regiment and a donation from Handley Page in memory of Cpl. R.K. Norry who was killed in a freefall parachuting accident, this was rebuilt at the new barracks at Credenhill. Those whose names are inscribed are said by surviving members to have "failed to beat the clock". At the suggestion of the then Commanding Officer, Dare Wilson, inscribed on the base of the clock is a verse from The Golden Journey to Samarkand by James Elroy Flecker:
== Bibliography == Wink, M (2009). "Mode of action and toxicology of plant toxins and poisonous plants". Mitt. Julius Kühn-Inst. 421: 93–112. Archived from the original on 18 March 2014. Retrieved 18 March 2014.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.